查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679110

生技药品CDMO 市场 - 全球和区域分析：按细胞类型、适应症、分子类型和区域 - 分析和预测（2025-2035 年）

Biologics CDMO Market - A Global and Regional Analysis: Focus on Cell Type, Indication, Molecule Type, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 120 Pages | 商品交期: 1-5个工作天内

价格
简介目录

由于生物製药需求的不断增加以及开发和製造流程外包的趋势日益增长，全球生技药品CDMO 市场规模正在快速成长。

製药公司越来越依赖生技药品CDMO 来处理复杂生物製药的生产，这需要专业知识、先进的基础设施和严格的法规遵循。将业务外包给生技药品CDMO 可使公司简化业务、降低成本并加快产品上市时间，使他们能够更专注于研发方面的核心竞争力。

生技药品CDMO 市场的扩张受到多种因素的推动，包括癌症、糖尿病和自体免疫疾病等慢性病的发生率不断上升，这推动了对创新生技药品疗法的需求。此外，生物技术的进步推动了下一代生技药品的开发，包括单株抗体、细胞和基因治疗药物以及重组蛋白。随着世界人口老化对这些疗法的需求越来越大，製药公司正在寻找灵活、可扩展的製造解决方案。因此，生技药品CDMO 市场预计将保持强劲的成长轨迹，并在不断发展的製药产业中发挥关键作用。

随着製药公司越来越多地使用生物製药CDMO 来加速生物製药的开发和商业化，生物製药CDMO 市场预计将继续成长。生技药品CDMO 提供全面的服务，包括上游工程、下游和分析服务，使製药公司能够更快、更有效地将生技药品推向市场。随着对生技药品的需求不断增加，生技药品CDMO 在优化生产和确保高品质製造方面发挥关键作用。

生技药品CDMO 市场也受惠于大量投资，以扩大 CDMO 产能，满足对生技药品製造服务日益增长的需求。为了保持竞争力并提高业务效率，生技药品CDMO 正在采用一次性生物反应器和连续製造等先进技术。这些创新有助于提高生技药品製造的扩充性、降低成本并增加灵活性。由于不断进步和对外包服务的日益依赖，生技药品CDMO 市场预计将在未来几年持续成长。

生技药品CDMO市场的出现和扩张深刻地改变了生物製药产业。生技药品CDMO 透过提供专业知识、最尖端科技和可扩展的解决方案，成为加速药物开发和製造的关键推动因素。生技药品CDMO 提供了一种具有成本效益的替代方案，尤其是对于新兴企业和小型公司而言，它减少了对大量资本投资的需求，同时降低了与复杂监管环境相关的风险。此外，生技药品CDMO 的全球企业发展和多样化能力使製药公司能够更轻鬆地适应当地的法规结构，从而促进生物製造的全球化。生技药品CDMO 领域的竞争推动着不断创新和技术进步，刺激了整个生物製药生态系统的进步。一家领先的专门从事生技药品的 CDMO 正在利用先进的蛋白质表现系统来加速治疗性蛋白质的开发和可扩展生产，确保高产量、纯度和法规遵循。作为策略合作伙伴，生技药品CDMO 在提高产业产能、灵活性和效率以满足全球对生技药品日益增长的需求方面发挥着至关重要的作用。

本报告研究了全球生技药品CDMO 市场，概述了市场状况以及按细胞类型、适应症、分子类型和地区分類的趋势，并介绍了市场参与者的概况。

目录

执行摘要

研究范围

第 1 章 全球生技药品CDMO 市场概览

  • 市场展望
  • 产业展望
  • 市场动态

2. 2024 年至 2035 年全球生技药品CDMO 市场分析（依细胞类型划分，百万美元）

  • 细胞类型摘要
  • 哺乳类
  • 微生物
  • 其他的

3. 全球生技药品CDMO 市场分析（依适应症划分），百万美元，2024 年至 2035 年

  • 适应症摘要
  • 肿瘤学
  • 自体免疫疾病
  • 感染疾病
  • 神经病学
  • 其他的

4. 全球生技药品CDMO 市场分析（以分子型态），百万美元，2024-2035 年

  • 分子类型摘要
  • 单株抗体
  • 重组蛋白
  • 疫苗
  • 荷尔蒙
  • 其他的

5. 2024 年至 2035 年全球生技药品CDMO 市场分析（按地区划分，百万美元）

  • 区域摘要
  • 驱动因素与限制因素
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

6. 全球生技药品CDMO 市场竞争基准化分析与公司概况

  • 竞争性基准化分析
  • 竞争格局
    • 各公司的主要策略和发展
    • 关键进展
    • 企业市场占有率分析/公司持股分析
  • 公司简介
    • AbbVie
    • AGC Biologics
    • Binex Co. Ltd.
    • Catalent, Inc.
    • Lonza Group
    • Novartis AG
    • Paraxel International Corporation
    • Samsung Biologics
    • Toyobo Co. Ltd.
    • Boehringer Ingelheim International GmbH
简介目录
Product Code: BHL1501SB

Global Biologics CDMO Market Overview

The global biologics CDMO market is experiencing rapid growth, driven by the increasing demand for biologic therapies and the growing trend of outsourcing development and manufacturing processes. Pharmaceutical companies are increasingly relying on biologics CDMOs to handle the complexities of biologic drug production, which requires specialized expertise, advanced infrastructure, and stringent regulatory compliance. By outsourcing to biologics CDMOs, companies can streamline operations, reduce costs, and accelerate time-to-market, allowing them to focus more on their core competencies in research and development.

Several factors are fueling the expansion of the biologics CDMO market, including the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which drive the need for innovative biologic treatments. Additionally, advancements in biotechnology are enabling the development of next-generation biologics, including monoclonal antibodies, cell and gene therapies, and recombinant proteins. The aging global population is further increasing the demand for these therapies, prompting pharmaceutical companies to seek flexible and scalable manufacturing solutions. As a result, the biologics CDMO market is expected to continue its strong growth trajectory, playing a crucial role in the evolving pharmaceutical landscape.

The biologics CDMO market is well-positioned for continued growth as pharmaceutical companies increasingly turn to biologics CDMOs to accelerate the development and commercialization of biologic therapies. Biologics CDMOs offer a comprehensive range of services, including upstream processing, downstream processing, and analytical services, enabling pharmaceutical companies to bring their biologics products to market more quickly and efficiently. As the demand for biologics continues to rise, biologics CDMOs are playing a crucial role in optimizing production and ensuring high-quality manufacturing.

The biologics CDMO market is also benefiting from significant investments in expanding CDMO capacity to meet the increasing demand for biologics manufacturing services. To stay competitive and enhance operational efficiency, biologics CDMOs are adopting advanced technologies such as single-use bioreactors and continuous manufacturing. These innovations help improve scalability, reduce costs, and enhance flexibility in biologics production. With continuous advancements and increasing reliance on outsourced services, the biologics CDMO market is poised for sustained growth in the coming years.

Industry Impact

The emergence and expansion of the biologics CDMO market have profoundly reshaped the biopharmaceutical industry. Biologics CDMOs serve as critical enablers of accelerated drug development and manufacturing, offering specialized expertise, cutting-edge technologies, and scalable solutions. By providing cost-efficient alternatives, particularly for startups and smaller enterprises, biologics CDMOs reduce the need for substantial capital investment while mitigating risks associated with complex regulatory landscapes. Additionally, the global reach and diverse capabilities of biologics CDMOs have contributed to the globalization of biomanufacturing, allowing pharmaceutical companies to navigate regional regulatory frameworks with greater ease. The competitive nature of the biologics CDMO sector fosters continuous innovation and technological advancements, driving progress across the entire biopharmaceutical ecosystem. Leading CDMOs specializing in biologics leverage advanced protein expression systems to accelerate the development and scalable production of therapeutic proteins, ensuring high yield, purity, and regulatory compliance. As strategic partners, biologics CDMOs enhance industry capacity, flexibility, and efficiency, playing an indispensable role in meeting the growing demand for biologic drugs worldwide.

Market Segmentation:

Segmentation 1: by Cell Type

  • Mammalian
  • Microbial
  • Others

Mammalian Segment to Dominate the Global Biologics CDMO Market (by Cell Type)

The mammalian segment dominated the global biologics CDMO market (by cell type) in FY2024, driven by its ability to accurately replicate complex proteins with high bioactivity and minimal post-translational modifications. Widely preferred for biopharmaceutical production, mammalian cell lines are particularly suited for manufacturing monoclonal antibodies, which constitute a significant share of biologic drugs. Offering scalability, robust performance, and compatibility with the intricate demands of therapeutic protein production, mammalian cell cultures play a crucial role in advancing biomanufacturing. As the biologics CDMO market continues to grow, the prominence of mammalian cell culture technology underscores its importance in meeting the global demand for cutting-edge biopharmaceuticals.

Segmentation 2: by Indication

  • Oncology
  • Auto-Immune Diseases
  • Infectious Diseases
  • Neurology
  • Others

Oncology Segment to Dominate the Global Biologics CDMO Market (by Indication)

The oncology segment led the global biologics CDMO market (by indication) in FY2024, driven by the surge in cancer research and the development of targeted therapies and immunotherapies. A significant portion of biopharmaceutical innovations is focused on oncology, leading biologics CDMOs to increasingly specialize in manufacturing monoclonal antibodies, cell-based therapies, and other cancer-targeting biologics. This trend underscores the growing emphasis on personalized medicine and the need for advanced manufacturing capabilities to address the complexities of oncology treatments, reinforcing the pivotal role of biologics CDMOs in supporting the evolving landscape of cancer therapeutics.

Segmentation 3: by Molecule Type

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Hormones
  • Others

Monoclonal Antibodies Segment to Dominate the Global Biologics CDMO Market (by Molecule Type)

The monoclonal antibodies (mAbs) segment dominated the global biologics CDMO market (by molecule type) in FY2024, driven by their widespread adoption in treating cancer, autoimmune disorders, and infectious diseases. As precision medicine continues to gain momentum, mAbs offer highly targeted and specific therapeutic approaches, further increasing their demand. This surge has led biologics CDMOs to experience growing requests for the development and manufacturing of monoclonal antibodies, reinforcing their critical role in the evolving landscape of biologic drug development and advanced therapeutics.

Segmentation 4: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The biologics CDMO market in the Asia-Pacific (APAC) region is experiencing rapid growth, driven by increasing demand for biopharmaceuticals, technological advancements, and the rising burden of chronic diseases. Among APAC countries, China is leading the market, fueled by strong government support, a growing biosimilars industry, and an expanding biomanufacturing infrastructure. The country's strategic investments in biologics production, coupled with evolving regulatory frameworks that favor contract biomanufacturing, have positioned China as a key hub for biologics CDMO services in the region.

Recent Developments in the Global Biologics CDMO Market

  • In November 2023, Boehringer Ingelheim International GmbH expanded the application of gene data biologics to DMPK operations.
  • In November 2023, Lonza introduced the GS Effex cell line to support biotech companies in advancing the development of therapeutic antibodies.
  • In October 2023, Lonza entered into a commercial agreement with Vaxcyte for the global production of broad-spectrum pneumococcal conjugate vaccines (PCVs).
  • In August 2023, AGC Biologics completed the expansion of its cell and gene therapy (CGT) manufacturing facility in Milan.
  • In August 2023, AGC Biologics announced a partnership with Asahi Kasei Pharma Corporation to manufacture clinical drug substances for antibody-based therapies.
  • In July 2023, Boehringer Ingelheim International GmbH launched its adalimumab biosimilar, adalimumab-adbm (Cyltezo), for commercial use in the U.S.
  • In July 2023, Biocon Biologics introduced a biosimilar version of AbbVie's rheumatoid arthritis drug Humira in the U.S.
  • In March 2023, Catalent, Inc. obtained a license for Bhami Research Laboratory Technology to enhance biologics formulation development.

Demand - Drivers, Restraints, and Opportunities

Market Drivers:

  • Growing Biologics Approvals and Development: The global biologics CDMO market is witnessing significant expansion, driven by the rising number of approvals for biologics and biosimilars. This surge highlights the increasing importance of biopharmaceuticals in addressing diverse medical conditions and the growing pipeline of innovative biologic drugs. As regulatory bodies worldwide continue to approve new biologics and biosimilars, pharmaceutical companies are increasingly relying on biologics CDMO services to fulfill the rising demand for specialized manufacturing expertise. The growing role of biologics CDMO providers underscores their critical contribution to the evolving biopharmaceutical landscape.
  • Rising Prevalence of Chronic Infectious Diseases
  • Advantages of Investments in Contract Manufacturing Facilities

Market Restraints:

  • Stringent Regulatory Requirements: The biologics CDMO market encounters significant constraints due to stringent regulatory requirements. The highly regulated nature of the biopharmaceutical industry, marked by rigorous compliance standards and stringent quality control measures, poses challenges for biologics CDMO providers. Navigating complex regulatory frameworks demands substantial expertise, resources, and continuous adaptation to evolving compliance expectations, making regulatory adherence a critical hurdle for biologics CDMO operations.
  • Shortage of Skilled Professionals in Bioprocessing and Biomanufacturing

Market Opportunities:

  • New Outsourcing Opportunities in China: The surge in investments in China's biologics CDMO market is fueled by the growing influx of biosimilars and innovative drugs, the rising demand for expanded manufacturing capacity, and evolving regulatory policies. To address both global and domestic market needs, Chinese regulatory authorities took a significant step by permitting contract biomanufacturing within the country. This regulatory shift has accelerated the growth of biologics CDMO services in China, attracting increased investment and strengthening the nation's position in the global biopharmaceutical landscape.
  • Potential for Additional CDMO and Big Pharma Alliances

How can this report add value to an organization?

Workflow/Innovation Strategy: The biologics CDMO market (by molecule type) is categorized based on various molecular types utilized in biologics development. Additionally, the study offers a comprehensive analysis of different cell types and indications, providing readers with a deeper understanding of the key components shaping the biologics manufacturing landscape.

Growth/Marketing Strategy: The biologics CDMO market's growth and marketing strategy are driven by a combination of technical excellence, strategic collaborations, and global market positioning. Biologics CDMOs capitalize on their specialized expertise in bioprocessing and manufacturing to provide comprehensive solutions tailored to the needs of biopharmaceutical companies. By leveraging advanced technologies, regulatory expertise, and scalable production capabilities, CDMOs strengthen their competitive edge and expand their market presence in the evolving biopharmaceutical landscape.

Competitive Strategy: The study provides an in-depth analysis and profiling of key players in the global biologics CDMO market, highlighting new product launches, acquisitions, expansions, and strategic collaborations. A detailed competitive benchmarking has been conducted to offer insights into how these players compare, presenting a clear view of the market landscape. Additionally, a comprehensive examination of competitive strategies, including partnerships, agreements, and collaborations, helps identify untapped revenue opportunities, enabling a deeper understanding of growth prospects within the biologics CDMO market.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • This report primarily focuses on the various cell types, molecule types, and indications within the global biologics CDMO market.
  • The market analysis is conducted in US dollars (US$), with all other currencies converted to US$ based on the average exchange rate for the respective year.
  • Currency conversion rates have been sourced from the historical exchange rates available on the Oanda website.
  • The insights presented in this report are derived from comprehensive primary interviews, surveys, and secondary research.
  • In cases where direct data was unavailable, proxy indicators and extrapolation methods were utilized.
  • Future economic downturns have not been factored into the market estimations and forecasts.
  • The current technologies used in the industry are assumed to remain consistent throughout the forecast period, with no major technological breakthroughs anticipated.

Primary Research

The primary sources involve industry experts from the biologics CDMO stakeholders. Respondents such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research

This research study involves the usage of extensive secondary research, directories, company websites, and annual reports. It also makes use of databases, such as Hoovers, Bloomberg, Businessweek, and Factiva, to collect useful and effective information for an extensive, technical, market-oriented, and commercial study of the global market. In addition to the aforementioned data sources, the study has been undertaken with the help of other data sources and websites, such as the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), World Health Organization (WHO), National Center for Biotechnology Information, and others.

The key data points taken from the secondary sources include:

  • Segmentations, split-ups, and percentage shares
  • Data for market value
  • Key industry trends of the top players in the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The biologics CDMO market is undergoing rapid expansion, solidifying its role as a crucial component of the biopharmaceutical industry. This dynamic sector is driven by the increasing demand for outsourcing services in the development and manufacturing of biologic drugs. Biologics, including monoclonal antibodies, recombinant proteins, and gene therapies, constitute a rapidly growing segment within the pharmaceutical landscape. As pharmaceutical and biotech companies strive to bring innovative biologics to market, they increasingly rely on biologics CDMO providers for specialized expertise, cutting-edge technologies, and cost-efficient solutions. The market is characterized by a diverse range of biologics CDMO players, each offering unique capabilities across the entire biologics development and manufacturing value chain.

With a global footprint, biologics CDMO providers are well-equipped to meet the industry's growing demand for flexible, high-quality, and efficient solutions in biologics development and manufacturing. As the biopharmaceutical market continues to expand, the biologics CDMO market is set to play a pivotal role in accelerating the transition of innovative therapies from concept to commercialization. By leveraging advanced technologies, regulatory expertise, and scalable production capabilities, biologics CDMO firms are becoming indispensable partners in the evolving biopharmaceutical landscape.

Some of the prominent companies in this market are:

  • AbbVie Inc.
  • AGC Biologics
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc
  • Lonza
  • Novartis AG
  • Parexel International Corporation
  • Samsung Biologics
  • Toyobo Co., Ltd.
  • WuXi Bio
  • Catalent
  • Fujifilm Diosynth

Companies that are not a part of the aforementioned pool have been well-represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Global Biologics CDMO Market Overview

  • 1.1 Market Outlook
    • 1.1.1 Definitions
    • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.3 Market Size, 2024 - 2035 (US$)
    • 1.1.4 Market Growth Scenario
      • 1.1.4.1 Realistic Scenario
      • 1.1.4.2 Optimistic Scenario
      • 1.1.4.3 Pessimistic Scenario
  • 1.2 Industry Outlook
    • 1.2.1 Introduction
    • 1.2.2 Market Overview and Ecosystem
    • 1.2.3 Key Trends
    • 1.2.4 Market Footprint
    • 1.2.5 Patent Analysis
    • 1.2.6 Factors Considered while Outsourcing to CDMO
    • 1.2.7 Regulatory Landscape / Compliances
  • 1.3 Market Dynamics
    • 1.3.1 Market Opportunities and Trends
    • 1.3.2 Market Drivers
      • 1.3.2.1 Impact Analysis
    • 1.3.3 Market Restraints
      • 1.3.3.1 Impact Analysis

2. Global Biologics CDMO Market Analysis (By Cell Type), $ Million, 2024-2035

  • 2.1 Cell Type Summary
  • 2.2 Mammalian
  • 2.3 Microbial
  • 2.4 Others

3. Global Biologics CDMO Market Analysis (By Indication), $ Million, 2024-2035

  • 3.1 Indication Summary
  • 3.2 Oncology
  • 3.3 Auto-Immune Diseases
  • 3.4 Infectious Diseases
  • 3.5 Neurology
  • 3.6 Others

4. Global Biologics CDMO Market Analysis (By Molecule Type), $ Million, 2024-2035

  • 4.1 Molecule Type Summary
  • 4.2 Monoclonal Antibodies
  • 4.3 Recombinant Proteins
  • 4.4 Vaccines
  • 4.5 Hormones
  • 4.6 Others

5. Global Biologics CDMO Market Analysis (By Region), $ Million, 2024-2035

  • 5.1 Regional Summary
  • 5.2 Drivers and Restraints
    • 5.2.1 North America
      • 5.2.1.1 By Cell Type
      • 5.2.1.2 By Molecule Type
        • 5.2.1.2.1 North America (by Country)
          • 5.2.1.2.1.1 U.S
          • 5.2.1.2.1.1.1 By Cell Type.
          • 5.2.1.2.1.1.2 By Molecule Type
          • 5.2.1.2.1.2 Canada
          • 5.2.1.2.1.2.1 By Cell Type.
          • 5.2.1.2.1.2.2 By Molecule Type
    • 5.2.2 Europe
      • 5.2.2.1 By Cell Type
      • 5.2.2.2 By Molecule Type
        • 5.2.2.2.1 Europe (by Country)
          • 5.2.2.2.1.1 Germany
          • 5.2.2.2.1.1.1 By Cell Type
          • 5.2.2.2.1.1.2 By Molecule Type
          • 5.2.2.2.1.2 U.K.
          • 5.2.2.2.1.2.1 By Cell Type
          • 5.2.2.2.1.2.2 By Molecule Type
          • 5.2.2.2.1.3 France
          • 5.2.2.2.1.3.1 By Cell Type
          • 5.2.2.2.1.3.2 By Molecule Type
          • 5.2.2.2.1.4 Italy
          • 5.2.2.2.1.4.1 By Cell Type
          • 5.2.2.2.1.4.2 By Molecule Type
          • 5.2.2.2.1.5 Spain
          • 5.2.2.2.1.5.1 By Cell Type
          • 5.2.2.2.1.5.2 By Molecule Type
          • 5.2.2.2.1.6 Rest of Europe
          • 5.2.2.2.1.6.1 By Cell Type
          • 5.2.2.2.1.6.2 By Molecule Type
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 By Cell Type
      • 5.2.3.2 By Molecule Type
        • 5.2.3.2.1 Asia-Pacific (by Country)
          • 5.2.3.2.1.1 Japan
          • 5.2.3.2.1.1.1 By Cell Type
          • 5.2.3.2.1.1.2 By Molecule Type
          • 5.2.3.2.1.2 China
          • 5.2.3.2.1.2.1 By Cell Type
          • 5.2.3.2.1.2.2 By Molecule Type
          • 5.2.3.2.1.3 India
          • 5.2.3.2.1.3.1 By Cell Type
          • 5.2.3.2.1.3.2 By Molecule Type
          • 5.2.3.2.1.4 Australia
          • 5.2.3.2.1.4.1 By Cell Type
          • 5.2.3.2.1.4.2 By Molecule Type
          • 5.2.3.2.1.5 Rest-of-Asia-Pacific
          • 5.2.3.2.1.5.1 By Cell Type
          • 5.2.3.2.1.5.2 By Molecule Type
    • 5.2.4 Latin America
      • 5.2.4.1 By Cell Type
      • 5.2.4.2 By Molecule Type
        • 5.2.4.2.1 Latin America (by Country)
          • 5.2.4.2.1.1 Brazil
          • 5.2.4.2.1.1.1 By Cell Type
          • 5.2.4.2.1.1.2 By Molecule Type
          • 5.2.4.2.1.2 Mexico
          • 5.2.4.2.1.2.1 By Cell Type
          • 5.2.4.2.1.2.2 By Molecule Type
          • 5.2.4.2.1.3 Rest-of-Latin America
          • 5.2.4.2.1.3.1 By Cell Type
          • 5.2.4.2.1.3.2 By Molecule Type
    • 5.2.5 Middle East & Africa
      • 5.2.5.1 By Cell Type
      • 5.2.5.2 By Molecule Type
        • 5.2.5.2.1 Middle East Africa (by Country)
          • 5.2.5.2.1.1 KSA
          • 5.2.5.2.1.1.1 By Cell Type
          • 5.2.5.2.1.1.2 By Molecule Type
          • 5.2.5.2.1.2 U.A.E.
          • 5.2.5.2.1.2.1 By Cell Type
          • 5.2.5.2.1.2.2 By Molecule Type
          • 5.2.5.2.1.3 Rest-of-Middle East and Africa
          • 5.2.5.2.1.3.1 By Cell Type
          • 5.2.5.2.1.3.2 By Molecule Type

6. Global Biologics CDMO Market - Competitive Benchmarking and Company Profiles

  • 6.1 Competitive Benchmarking
  • 6.2 Competitive Landscape
    • 6.2.1 Key Strategies and Developments by Company
      • 6.2.1.1 Funding Activities
      • 6.2.1.2 Mergers and Acquisitions
      • 6.2.1.3 Regulatory Approvals
      • 6.2.1.4 Partnerships, Collaborations, and Business Expansions
    • 6.2.2 Key Developments Analysis
    • 6.2.3 Company Share Analysis/ Company Position Analysis
  • 6.3 Company Profiles
    • 6.3.1 AbbVie
    • 6.3.2 AGC Biologics
    • 6.3.3 Binex Co. Ltd.
    • 6.3.4 Catalent, Inc.
    • 6.3.5 Lonza Group
    • 6.3.6 Novartis AG
    • 6.3.7 Paraxel International Corporation
    • 6.3.8 Samsung Biologics
    • 6.3.9 Toyobo Co. Ltd.
    • 6.3.10 Boehringer Ingelheim International GmbH